Jasper Therapeutics (JSPR) News Today → Trump convicted... now what? (From Stansberry Research) (Ad) Free JSPR Stock Alerts $24.00 -0.52 (-2.12%) (As of 10:20 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30, 2024 | globenewswire.comJasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024May 29, 2024 | globenewswire.comJasper Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 20, 2024 | markets.businessinsider.comBuy Rating for Jasper Therapeutics Amid Promising briquilimab Trials and Asthma Market PotentialMay 20, 2024 | marketbeat.comIeq Capital LLC Makes New $43,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Ieq Capital LLC acquired a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 54,500 shares of the company's stock, valued at approximately $43,000. Ieq Capital LLC owned 0.49% ofMay 17, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Jasper Therapeutics, Inc. (NASDAQ:JSPR) Issued By HC WainwrightJasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Analysts at HC Wainwright lifted their Q2 2024 earnings estimates for shares of Jasper Therapeutics in a report released on Wednesday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of (May 16, 2024 | markets.businessinsider.comBuy Rating on Jasper Therapeutics: High Hopes for Briquilimab’s Clinical TrialsMay 15, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Wednesday.May 15, 2024 | marketbeat.comResearch Analysts Offer Predictions for Jasper Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:JSPR)Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report issued on Tuesday, May 14th. William Blair analyst M. Phipps expects that the company will post earnings per share of ($0.91)May 14, 2024 | finanznachrichten.deJasper Therapeutics, Inc.: Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsMay 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Stereotaxis (STXS), Jasper Therapeutics (JSPR)May 14, 2024 | investorplace.comJSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comJasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsMay 13, 2024 | globenewswire.comJasper Therapeutics Announces Briquilimab Development Program in AsthmaMay 11, 2024 | marketbeat.comMonaco Asset Management SAM Takes Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Monaco Asset Management SAM purchased a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 249,563 shares of the company's stock, valued at apprMay 7, 2024 | globenewswire.comJasper Therapeutics to Present at Upcoming Investor Conferences in MayMay 7, 2024 | markets.businessinsider.comBriquilimab’s Market Potential and Competitive Advantage in Autoimmune Diseases: An Investment OpportunityMay 7, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Jasper Therapeutics (JSPR) with Buy RecommendationMay 6, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at HC WainwrightHC Wainwright assumed coverage on shares of Jasper Therapeutics in a research report on Monday. They set a "buy" rating and a $65.00 price target on the stock.May 4, 2024 | morningstar.comJasper Therapeutics Inc Ordinary SharesApril 29, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Position Raised by Fernwood Investment Management LLCFernwood Investment Management LLC increased its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 8.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor ownApril 25, 2024 | markets.businessinsider.comBuy Rating Affirmed: Jasper Therapeutics’ Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment MarketApril 3, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at Evercore ISIEvercore ISI assumed coverage on Jasper Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $65.00 price objective on the stock.April 2, 2024 | globenewswire.comJasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Buy" from AnalystsShares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have received an average recommendation of "Buy" from the seven research firms that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The aMarch 28, 2024 | msn.comRBC starts Jasper Therapeutics at outperform, cites market opportunityMarch 28, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Receives New Coverage from Analysts at Royal Bank of CanadaRoyal Bank of Canada began coverage on shares of Jasper Therapeutics in a report on Thursday. They set an "outperform" rating and a $70.00 price target for the company.March 21, 2024 | globenewswire.comJasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria TreatmentMarch 20, 2024 | finance.yahoo.comJasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders are retail investors with 42% ownership, institutions own 26%March 19, 2024 | globenewswire.comJasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible UrticariaMarch 18, 2024 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Earns Outperform Rating from Analysts at TD CowenTD Cowen assumed coverage on shares of Jasper Therapeutics in a research report on Monday. They issued an "outperform" rating for the company.March 16, 2024 | finance.yahoo.comJSPR Jul 2024 40.000 callMarch 15, 2024 | finanznachrichten.deJasper Therapeutics, Inc.: New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi AnemiaMarch 15, 2024 | globenewswire.comNew Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi AnemiaMarch 14, 2024 | msn.comEntrada Therapeutics GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85MMarch 13, 2024 | insidertrades.comJeetinder Singh Mahal Sells 900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) StockMarch 12, 2024 | marketbeat.comInsider Selling: Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells 900 Shares of StockJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) COO Jeetinder Singh Mahal sold 900 shares of Jasper Therapeutics stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $26.44, for a total transaction of $23,796.00. Following the transaction, the chief operating officer now directly owns 25,009 shares in the company, valued at $661,237.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 11, 2024 | finance.yahoo.comJSPR Oct 2024 30.000 callMarch 10, 2024 | finance.yahoo.comJSPR Oct 2024 17.500 callMarch 10, 2024 | finance.yahoo.comJSPR Apr 2024 35.000 callMarch 7, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been given a consensus rating of "Buy" by the six research firms that are covering the company, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issMarch 7, 2024 | marketbeat.comOppenheimer Reiterates "Outperform" Rating for Jasper Therapeutics (NASDAQ:JSPR)Oppenheimer restated an "outperform" rating and set a $80.00 target price on shares of Jasper Therapeutics in a report on Thursday.March 7, 2024 | marketbeat.comJasper Therapeutics, Inc. to Post Q1 2024 Earnings of ($1.19) Per Share, Capital One Financial Forecasts (NASDAQ:JSPR)Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at Capital One Financial lifted their Q1 2024 earnings estimates for Jasper Therapeutics in a research report issued to clients and investors on Monday, March 4th. Capital One Financial analyst T. Chiang now anticipates that tMarch 6, 2024 | finance.yahoo.comJSPR Mar 2024 22.500 putMarch 6, 2024 | investorplace.comJSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023March 6, 2024 | marketbeat.comWilliam Blair Weighs in on Jasper Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:JSPR)Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities researchers at William Blair upped their Q1 2024 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report released on Monday, March 4th. William Blair analyst M. Phipps now expects that the company will earnMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Jasper Therapeutics’ Progress and Potential in Addressing Unmet Needs in Chronic Urticaria TreatmentMarch 4, 2024 | finanznachrichten.deJasper Therapeutics, Inc.: Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comJasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate DevelopmentsMarch 3, 2024 | finance.yahoo.comJSPR Mar 2024 15.000 put Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s arrest is phase one (Ad)In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. JSPR Media Mentions By Week JSPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼0.000.76▲Average Medical News Sentiment JSPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼02▲JSPR Articles Average Week Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DocGo News BioCryst Pharmaceuticals News Cullinan Therapeutics News Tarsus Pharmaceuticals News Ginkgo Bioworks News 4D Molecular Therapeutics News Immatics News Autolus Therapeutics News Relay Therapeutics News Humacyte News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored